A new trading day began on Friday, with ARS Pharmaceuticals Inc (NASDAQ: SPRY) stock price up 3.67% from the previous day of trading, before settling in for the closing price of $14.72. SPRY’s price has ranged from $3.38 to $17.08 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -34.76% over the past five years. Meanwhile, its annual earnings per share averaged -11.21%. With a float of $49.21 million, this company’s outstanding shares have now reached $96.41 million.
Let’s look at the performance matrix of the company that is accounted for 26 employees. In terms of profitability, gross margin is 86.81%, operating margin of -12071.49%, and the pretax margin is -9536.81%.
ARS Pharmaceuticals Inc (SPRY) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of ARS Pharmaceuticals Inc is 49.24%, while institutional ownership is 39.32%. The most recent insider transaction that took place on Oct 16 ’24, was worth 200,000. In this transaction Chief Financial Officer of this company sold 12,500 shares at a rate of $16.00, taking the stock ownership to the 4,949 shares. Before that another transaction happened on Oct 15 ’24, when Company’s CHIEF MEDICAL OFFICER sold 100,000 for $14.88, making the entire transaction worth $1,487,595. This insider now owns 1,298,499 shares in total.
ARS Pharmaceuticals Inc (SPRY) Latest Financial update
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -0.16 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.27 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -11.21% per share during the next fiscal year.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Trading Performance Indicators
Here are ARS Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 32.78. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3067.20.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.47, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.83 in one year’s time.
Technical Analysis of ARS Pharmaceuticals Inc (SPRY)
ARS Pharmaceuticals Inc (NASDAQ: SPRY) saw its 5-day average volume 0.84 million, a positive change from its year-to-date volume of 0.77 million. As of the previous 9 days, the stock’s Stochastic %D was 20.38%. Additionally, its Average True Range was 0.89.
During the past 100 days, ARS Pharmaceuticals Inc’s (SPRY) raw stochastic average was set at 80.90%, which indicates a significant increase from 38.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.10% in the past 14 days, which was lower than the 69.41% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.05, while its 200-day Moving Average is $10.32. Nevertheless, the first resistance level for the watch stands at $15.70 in the near term. At $16.15, the stock is likely to face the second major resistance level. The third major resistance level sits at $16.83. If the price goes on to break the first support level at $14.57, it is likely to go to the next support level at $13.89. The third support level lies at $13.44 if the price breaches the second support level.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Key Stats
With a market capitalization of 1.53 billion, the company has a total of 96,942K Shares Outstanding. Currently, annual sales are 30 K while annual income is -54,370 K. The company’s previous quarter sales were 500 K while its latest quarter income was -12,520 K.
